

## Are current Polish guidelines for prophylactic mastectomy sufficient?

Stachowski Adam <sup>[1]</sup>, Cybulski Cezary <sup>[1]</sup>, Gronwald Jacek <sup>[1]</sup>, Huzarski Tomasz <sup>[1]</sup>, Dębniak Tadeusz <sup>[1]</sup>, Matuszczak Milena <sup>[1]</sup>, Kiljańczyk Adam<sup>[1]</sup>, Szwiec Marek <sup>[2]</sup>, Tomiczek-Szwiec Joanna <sup>[3]</sup>, Jasiewicz Andrzej <sup>[4]</sup>, Kluz Tomasz <sup>[5]</sup>, Prusaczyk Artur <sup>[6]</sup>, Kilar-Kobierzycka Ewa <sup>[7]</sup>, Godlewski Dariusz <sup>[8]</sup>, Zegarski Wojciech <sup>[9]</sup>, Monika Siołek <sup>[10]</sup>, Kozak-Klonowska Beata <sup>[10]</sup>, Rafał Wiśniowski <sup>[11]</sup>, Renata Posmyk <sup>[12]</sup>, Lubiński Jan <sup>[1]</sup>

1. International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University in Szczecin, Szczecin, Poland.
2. Department of Surgery and Oncology, University of Zielona Góra, Zielona Góra, Poland
3. Department of Histology, Department of Biology and Genetics, Faculty of Medicine, University of Opole, 45-040 Opole, Poland.
4. Genetic Counseling Center, Subcarpatian Oncological Hospital, 18 Bielawskiego Str., 36-200 Brzozów, Poland.
5. Department of Gynecology, Gynecology Oncology and Obstetrics, Institute of Medical Sciences, Medical College, Rzeszow University, Rejtana 16c, 35-959 Rzeszow, Poland.
6. Medical and Diagnostic Center, Niklinowa 9, 08-110 Siedlce, Poland.
7. Department of Oncology, District Specialist Hospital, Leśna 27-29 Str., 58-100 Świdnica, Poland.
8. OPEN, Kazimierza Wielkiego 24 Str., 61-863 Poznań, Poland.
9. Department of Oncological Surgery, Oncology Center in Bydgoszcz, Medical College in Bydgoszcz, Nicolaus Copernicus University in Toruń, Poland
10. Holycross Cancer Center, Artwińskiego 3 Str., 25-734 Kielce, Poland.
11. Regional Oncology Hospital, Wyzwolenia 18 Str., 43-300 Bielsko Biała, Poland.
12. Department of Clinical Genetics, Podlaskie Medical Center, 15-399 Białystok, Poland.

Currently, the Polish Ministry of Health covers the costs of prophylactic mastectomy only for BRCA1/2 mutation carriers or women from families with aggregation of breast cancer. However, these regulations are outdated and should be changed to make the above-mentioned procedure available to other women at high risk of developing breast cancer. Therefore, we suggest covering the costs of mastectomy for carriers of TP53, PTEN, PALB2 mutations regardless of breast cancer family history. In the case of CHEK2 mutations, we suggest limiting access only to women with high-risk variants. These include primarily carriers of protein-shortening variants with a positive family history. We estimated the number of additional prophylactic mastectomies if the Guidelines were changed as proposed by us to be 450.